ライフサイエンスコーパス: gastrointestinal infection

1 against EHEC O157:H7 using a murine model of gastrointestinal infection.

2 erance in a Caenorhabditis elegans model for gastrointestinal infection.

3 ll surface mucin, is an important barrier to gastrointestinal infection.

4 y response to limit invasive respiratory and gastrointestinal infection.

5 in addition to inlA appear to contribute to gastrointestinal infection.

6 uiring surgical management similar to direct gastrointestinal infection.

7 lmonella enterica serovar Typhimurium during gastrointestinal infections.

8 1917, a human probiotic strain used to treat gastrointestinal infections.

9 or their prophylactic or therapeutic role in gastrointestinal infections.

10 or the development of novel vaccines against gastrointestinal infections.

11 e to the development of new vaccines against gastrointestinal infections.

12 a nosocomial pathogen that can cause severe gastrointestinal infections.

13 otile bacterium, is a leading cause of human gastrointestinal infections.

14 eonates are considered highly susceptible to gastrointestinal infections.

15 prerequisite to protective immunity against gastrointestinal infections.

16 l therapeutic strategies in the treatment of gastrointestinal infections.

17 s), enteritis necroticans, and non-foodborne gastrointestinal infections.

18 sures to new pathogenic organisms that cause gastrointestinal infections.

19 rs (ABO, Lewis, and P) associated with other gastrointestinal infections.

20 1.8%), surgical-site infections (21.8%), and gastrointestinal infections (17.1%).

21 er respiratory tract infections (171 [22%]), gastrointestinal infections (64 [8%]), eye, ear, nose, a

22 effect of vitamin A supplementation on viral gastrointestinal infections among young children living

23 To investigate in a cohort with previous gastrointestinal infection and a control group the preva

24 n of inlA is important for cell invasion and gastrointestinal infection and suggest that sigmaB-regul

25 -3 (5-HT3) antagonists, and the treatment of gastrointestinal infections and chronic abdominal pain.

26 a for the treatment of patients with chronic gastrointestinal infections and inflammatory bowel disea

27 All these patients are at similar risk of gastrointestinal infections, and the subsequent morbidit

28 Gastrointestinal infections are a frequent and important

29 is study, we report the human health risk of gastrointestinal infection associated with inhalation ex

30 ets may be beneficial in the defense against gastrointestinal infections, but their sustained activat

31 stressor exposure can have at the onset of a gastrointestinal infection by its ability to render a re

32 Ysa type III secretion (T3S) system enhances gastrointestinal infection by Yersinia enterocolitica bv

33 As for other gastrointestinal infections, C difficile disease is asso

34 Children with gastrointestinal infections caused by Escherichia coli O

35 Treatment of gastrointestinal infections continues to be complicated

36 The incidence of gastrointestinal infections continues to increase and in

37 We demonstrate that gastrointestinal infection does indeed occur in humans a

38 risk was higher among children who had had a gastrointestinal infection during the first year of life

39 o patient developed a clinically significant gastrointestinal infection during the study.

40 Repeated gastrointestinal infections during the first year of lif

41 produced in response to localized Salmonella gastrointestinal infection enable the pathogen to succes

42 es from children with severe respiratory and gastrointestinal infections has generated interest in un

43 d 2006-2007 regarding the development of any gastrointestinal infections, hospitalizations, and presc

44 It is preceded by upper respiratory or gastrointestinal infection in about two-thirds of cases

45 introduction of surveillance of outbreaks of gastrointestinal infection in England and Wales in 1992.

46 r respiratory tract infection in addition to gastrointestinal infection in gnotobiotic pigs, confirmi

47 SARS-CoV) which causes acute respiratory and gastrointestinal infection in humans.

48 Gastrointestinal infections in children are a major caus

49 ost prevalent cause of antibiotic-associated gastrointestinal infections in health care facilities in

50 serovar Typhimurium (ST), a leading cause of gastrointestinal infections in humans, effects an overal

51 al presentation, diagnosis, and treatment of gastrointestinal infections in immunocompromised hosts i

52 Because gastrointestinal infections in immunocompromised persons

53 particularly during the past year, regarding gastrointestinal infections in immunocompromised persons

54 orted by the dose-response relationship) and gastrointestinal infections in the first year of life ma

55 al presentation, diagnosis, and treatment of gastrointestinal infections in the immunocompromised hos

56 article reviews what is new in the field of gastrointestinal infections in the immunocompromised hos

57 he pathogenesis, diagnosis, and treatment of gastrointestinal infections in the immunocompromised hos

58 diagnostic and therapeutic skills regarding gastrointestinal infections in the immunocompromised hos

59 Gastrointestinal infections in the immunocompromised hos

60 piratory infections and HBoV2 to HBoV4 cause gastrointestinal infections in young children.

61 ses (HBoVs) may cause severe respiratory and gastrointestinal infections in young children.

62 This technology can also be used to study gastrointestinal infections, inflammatory bowel disease,

63 sible for causing bronchitis, pneumonia, and gastrointestinal infections, is highly resistant to UV d

64 These findings indicate that early gastrointestinal infections may be relevant for CD devel

65 s in most hosts, then it is very likely that gastrointestinal infection occurs in humans as well.

66 Thus, if gastrointestinal infection occurs in most hosts, then it

67 show that following acute Toxoplasma gondii gastrointestinal infection of mice, control of commensal

68 ke infections, as some of the most important gastrointestinal infections of humankind.

69 n lansoprazole, all were free of significant gastrointestinal infections on long-term follow-up.

70 levels of investment relative to burden for gastrointestinal infections ( pound254 million, 9.7%), s

71 Here we show that during acute gastrointestinal infection, priming of monocytes for reg

72 pment of vaccines against the most important gastrointestinal infections remains a high priority.

73 acid suppressing medications and the risk of gastrointestinal infections remains controversial.

74 lial response, including host restriction of gastrointestinal infections such as HRV infection.

75 cin is far less effective against chlamydial gastrointestinal infection than against genital infectio

76 s, protozoans are more commonly the cause of gastrointestinal infections than are helminths.

77 Our results suggest that during a gastrointestinal infection, the immune response to comme

78 is and treatment of pathologies ranging from gastrointestinal infections to diabetes.

79 Here, we show that during a gastrointestinal infection, tolerance to commensals is l

80 es isolated from patients with uncomplicated gastrointestinal infection using DNA microarray analysis

81 genes with previously unproven phenotypes in gastrointestinal infection were tested in bovine ligated

82 Gastrointestinal infections were strongly associated wit

83 It often occurs after gastrointestinal infection with E. coli O157:H7, which p

84 The acute host response to gastrointestinal infection with invasive bacteria is cha

85 by acute renal failure, usually occurs after gastrointestinal infection with Shiga toxin 2 (Stx2)-pro

86 Typical HUS (ie, STEC-HUS) follows a gastrointestinal infection with STEC, whereas aHUS is as

87 although much less than that gained by prior gastrointestinal infection with the wild-type parent str

88 Campylobacter jejuni is a leading cause of gastrointestinal infections worldwide, due primarily to